These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 17546572)

  • 1. A quantitative approach to benefit-risk assessment of medicines--part 1: the development of a new model using multi-criteria decision analysis; part 2: the practical application of a new model.
    Mussen F; Salek S; Walker S
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S42-6. PubMed ID: 17546572
    [No Abstract]   [Full Text] [Related]  

  • 2. A quantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis.
    Mussen F; Salek S; Walker S
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S2-S15. PubMed ID: 17546573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A quantitative approach to benefit-risk assessment of medicines - part 2: the practical application of a new model.
    Mussen F; Salek S; Walker S; Phillips L
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S16-41. PubMed ID: 17546574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A decision analytic approach to a futility analysis of a phase II pharmaceutical study.
    Pallay A
    J Biopharm Stat; 2001 Nov; 11(4):209-25. PubMed ID: 12018776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a site-specific Ecological Risk Assessment for contaminated sites: part II. A multi-criteria based system for the selection of bioavailability assessment tools.
    Semenzin E; Critto A; Carlon C; Rutgers M; Marcomini A
    Sci Total Environ; 2007 Jun; 379(1):34-45. PubMed ID: 17434575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multiattribute model for evaluating the benefit-risk profiles of treatment alternatives.
    Felli JC; Noel RA; Cavazzoni PA
    Med Decis Making; 2009; 29(1):104-15. PubMed ID: 18812582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a site-specific ecological risk assessment for contaminated sites: part I. A multi-criteria based system for the selection of ecotoxicological tests and ecological observations.
    Critto A; Torresan S; Semenzin E; Giove S; Mesman M; Schouten AJ; Rutgers M; Marcomini A
    Sci Total Environ; 2007 Jun; 379(1):16-33. PubMed ID: 17439821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of PKPD relationships into benefit-risk analysis.
    Bellanti F; van Wijk RC; Danhof M; Della Pasqua O
    Br J Clin Pharmacol; 2015 Nov; 80(5):979-91. PubMed ID: 25940398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Safe administration of new drugs].
    Schou J; Pelkonen O; Saano V
    Duodecim; 1996; 112(11):1013-6. PubMed ID: 10592998
    [No Abstract]   [Full Text] [Related]  

  • 10. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk communication and risky choice in context: ambiguity and ambivalence hypothesis.
    Wang XT
    Ann N Y Acad Sci; 2008 Apr; 1128():78-89. PubMed ID: 18469216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit-risk analysis: a proposal using quantitative methods.
    Holden WL; Juhaeri J; Dai W
    Pharmacoepidemiol Drug Saf; 2003; 12(7):611-6. PubMed ID: 14558185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The application of genetic information for regulatory standard setting under the clean air act: a decision-analytic approach.
    Cullen AC; Corrales MA; Kramer CB; Faustman EM
    Risk Anal; 2008 Aug; 28(4):877-90. PubMed ID: 18631305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New painkillers inhibiting the physiological breakdown of endogenous opioids].
    Roques BP; Fournié-Zaluski MC; Wurm M
    Med Sci (Paris); 2012 May; 28(5):476-8. PubMed ID: 22643000
    [No Abstract]   [Full Text] [Related]  

  • 16. Development and field evaluation of a decision support model for anthelmintic treatments as part of a targeted selective treatment (TST) regime in lambs.
    Greer AW; Kenyon F; Bartley DJ; Jackson EB; Gordon Y; Donnan AA; McBean DW; Jackson F
    Vet Parasitol; 2009 Sep; 164(1):12-20. PubMed ID: 19409708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-criteria dynamic decision under uncertainty: a stochastic viability analysis and an application to sustainable fishery management.
    De Lara M; Martinet V
    Math Biosci; 2009 Feb; 217(2):118-24. PubMed ID: 19084541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Application of the Verena Tschudin decision model: ethical--moral decisions].
    Schadewaldt V
    Pflege Z; 2009 Sep; 62(9):522-5. PubMed ID: 19750966
    [No Abstract]   [Full Text] [Related]  

  • 20. A decision support system to facilitate management of patients with acute gastrointestinal bleeding.
    Chu A; Ahn H; Halwan B; Kalmin B; Artifon EL; Barkun A; Lagoudakis MG; Kumar A
    Artif Intell Med; 2008 Mar; 42(3):247-59. PubMed ID: 18063351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.